[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-508238-105":59,"doc-detail-508238-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","national-patient-safety-alert-2024007-shortage-of-pancreatic-enzyme-replacement-therapy-pert","National Patient Safety Alert - 2024/007 - Shortage of Pancreatic Enzyme Replacement Therapy (PERT)","","National Patient Safety Alert NatPSA/2024/007/DHSC addresses limited availability of pancreatic enzyme replacement therapy (PERT) and supersedes Medicine Supply Notification MSN/2024/054. It explains the disruption affecting Creon® (limited until 2026) and Nutrizym® 22 (out of stock until mid-August 2024), notes clinical use in pancreatic exocrine insufficiency, and states there is no clinical alternative to PERT. The alert sets time-limited actions for clinicians and pharmacists, including prescribing limits, prioritisation between strengths, dose optimisation considerations, and appropriate use of unlicensed imports with specialist referral when needed.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/national-patient-safety-alert-2024007-shortage-of-pancreatic-enzyme-replacement-therapy-pert/508238/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/national-patient-safety-alert-2024007-shortage-of-pancreatic-enzyme-replacement-therapy-pert/508238.png","ImageObject",300,407,{"name":92,"@type":93},"dhado","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-10-05",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the national patient safety alert NatPSA/2024/007/DHSC cover?","Question",{"text":112,"@type":113},"It covers a shortage of pancreatic enzyme replacement therapy (PERT), including background on the supply disruption and actions for prescribing and dispensing during the period of limited supplies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which PERT products are affected and what are the key supply constraints?",{"text":117,"@type":113},"Creon® 10,000 and 25,000 capsules are in limited supply until 2026, while Nutrizym® 22 capsules are out of stock until mid-August 2024. Pancrex V® capsules and powder remain available but cannot support increased demand.",{"name":119,"@type":110,"acceptedAnswer":120},"What immediate prescribing and dispensing actions are required for clinicians and pharmacists?",{"text":121,"@type":113},"Clinicians should prescribe a maximum one month’s supply at a time and prioritise available Creon 10,000 for patients unable to take Creon 25,000, and reserve Nutrizym® 22 for patients who cannot tolerate Creon. Pharmacists should supply only the equivalent of one month’s supply for repeat prescriptions in line with specified safety guidance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},508238,1791624399,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":81,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":39,"preview_page_count":4},5909893218464,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Chief Medical Officer Directorate Pharmacy and Medicines Division  \nT: 0131-244-2528  \nE: [irene.fazakerley@gov.scot](irene.fazakerley@gov.scot)  \n􀀅􀀇􀀈􀀉  \nIMMEDIATE MESSAGE TO:  \nMedical Directors NHS Boards  \nDirectors of Pharmacy  \n24 May 2024  \n  Dear Healthcare Professional,  \nNATIONAL PATIENT SAFETY ALERT/2024/007/DHSC SHORTAGE OF PANCREATIC ENZYME REPLACEMENT THERAPY (PERT)  \nThis National Patient Safety Alert supersedes the Medicine Supply Notification (MSN/2024/054) which was issued on 09 May 2024.There are limited supplies of pancreatic enzyme replacement therapies (PERT) .  \nThe Alert provides background and clinical information and actions for providers for onward transmission as below :  \nPlease could all Directors of Pharmacy please forward this alert to:-  \n● Chief Pharmacists  \n● Hospital Pharmacists  \n● Community Pharmacists  \nPlease could Medical Directors arrange to forward this alert on to:-  \n● General Practitoners  \n● Dispensing Doctors  \n● Respiratory Services  \n● Dietetics  \n● Hepatobiliary Services  \n● Cancer Services  \n● Relevant Clinics Private Healthcare providers  \nThank you for your co-operation.  \nYours sincerely  \nIRENE FAZAKERLEY  \nMedicines Policy Team  \nShortage of Pancreatic enzyme replacement therapy (PERT)  \n\n| Date of issue: | 24-May-24 | Reference no: | NatPSA/2024/007/DHSC |\n| --- | --- | --- | --- |\n| This alert is for action by: All organisations involved in prescribing and dispensing pancreatic enzyme replacement therapy (PERT) . |  |  |  |\n| This is a safety critical and complex National Patient Safety Alert. Implementation should be co-ordinated by an executive lead (or equivalent role in organisations without executive boards) and supported by clinical leaders in community pharmacy, GP practices and clinical leaders in pharmacy, dietetics, respiratory , hepatobiliary and cancer services. |  |  |  |\n\n\n| Explanation of identified safety issue: |\n| --- |\n| This alert supersedes the Medicine Supply Notification (MSN/2024/054) issued on the 9th May 2024.\u003Cbr>There are limited supplies of pancreatic enzyme replacement therapies (PERT) .\u003Cbr>• Creon® 10,000 and 25,000 capsules are in limited supply until 2026.\u003Cbr>• Nutrizym® 22 capsules are out of stock until midAugust 2024.\u003Cbr>• Pancrex V® capsules and powder remain available but are unable to support an increase in demand.\u003Cbr>The supply disruption of Creon® capsules is due to limited availability of active pharmaceutical ingredients and manufacturing constraints to produce the volumes required to meet demand.\u003Cbr>The supply disruption for Nutrizym® 22 capsules has been caused by a manufacturing issue and increased demand because of the Creon® supply issue.\u003Cbr>PERT is indicated for the treatment of pancreatic exocrine insufficiency such as in cystic fibrosis, pancreatic cancer, and pancreatitis. There is no clinical alternative to PERT.\u003Cbr>Unlicensed imports of Creon® capsules and alternative brands of PERT may be sourced, lead times vary.\u003Cbr>Information relating to imports is available below and on the SPS Medicines Supply Tool which also details any changes to resupply dates, updates to this communication and an up-to-date supply overview. |\n\n\n| \u003Cbr>Actions required |\n| --- |\n| Actions for clinicians and prescribers of PERT tobe completed 10/06/2024\u003Cbr>To remain in place only until the supply issues have resolved (see SPS Medicine Supply Tool):\u003Cbr>1. Clinicians should:\u003Cbr>a. prescribe a maximum of one month’s supply of PERT for all patients at a time.\u003Cbr>b. prioritise available Creon 10,000 capsules for patients unable to take Creon 25,000 capsules only. Note A\u003Cbr>c. prioritise remaining stock of Nutrizym® 22 capsules for patients unable to tolerate Creon capsules.\u003Cbr>d. where PERT is prescribed for indications other than cystic fibrosis, clinicians and prescribers should consider:\u003Cbr>• prescribing a proton pump inhibitor or H2 receptor antagonist to optimise efficacy Note B\u003Cbr>• if a dose reduction may be suitable for patients based on se","cbCaiuQos4dns4zP","https://ap.wps.com/l/cbCaiuQos4dns4zP","pdf",256025,"English","# Explanation of identified safety issue\n## Actions required\n## Additional information","[{\"question\":\"What does the national patient safety alert NatPSA/2024/007/DHSC cover?\",\"answer\":\"It covers a shortage of pancreatic enzyme replacement therapy (PERT), including background on the supply disruption and actions for prescribing and dispensing during the period of limited supplies.\"},{\"question\":\"Which PERT products are affected and what are the key supply constraints?\",\"answer\":\"Creon® 10,000 and 25,000 capsules are in limited supply until 2026, while Nutrizym® 22 capsules are out of stock until mid-August 2024. Pancrex V® capsules and powder remain available but cannot support increased demand.\"},{\"question\":\"What immediate prescribing and dispensing actions are required for clinicians and pharmacists?\",\"answer\":\"Clinicians should prescribe a maximum one month’s supply at a time and prioritise available Creon 10,000 for patients unable to take Creon 25,000, and reserve Nutrizym® 22 for patients who cannot tolerate Creon. Pharmacists should supply only the equivalent of one month’s supply for repeat prescriptions in line with specified safety guidance.\"}]","National Patient Safety Alert - 2024/007 - Shortage of Pancreatic Enzyme Replacement Therapy (PERT) | PDF",1791213605]